Primary Hyperaldosteronism

Summary

Primary hyperaldosteronism (PHA) is regarded as a rare disease with prevalence rates of 0.5 to 2% within the hypertensive population. Recent studies using more detailed screening procedures in small hypertensive cohorts have suggested that PHA may be more common than previously thought (3-18%). Since a validated and cost-effective routine screening protocol for this entity is not established, many clinicians are reluctant to consider PHA as an underlying cause for a patient's high blood pressure. The insufficient perception of PHA may have fatal consequences since most patients are curable by an operation and missing the diagnosis often leads to significant and irreversible end-organ damage.

This review focuses on the diagnosis of PHA and gives a rational and cost-effective flow chart for routine screening and differential diagnosis of PHA in hypertensive patients.

Primary hyperaldosteronism - Aldosterone - Plasma renin activity - Conn's syndrome - Screening and diagnosis

References

• 1 Anderson G H, Blakeman N, Streeten D H. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients.  J Hypertens. 1994;  12 609-615
• 2 Bernini G, Moretti A, Argenio G, Salvetti A. Primary aldosteronism in normokalemic patients with adrenal incidentalomas.  Eur J Endocrinol. 2002;  146 523-529
• 3 Biglieri E G, Schambelan M. The significance of elevated levels of plasma 18-hydroxycorticosterone in patients with primary aldosteronism.  J Clin Endocrin Metab. 1979;  49 87-91
• 4 Blumenfeld J D, Sealey J E, Schlussel Y, Vaughan E D, Sos T A, Atlas S A, Muller F B, Acevedo R, Ulick S, Laragh J H. Diagnosis and treatment of primary hyperaldosteronism.  Ann Intern Med. 1994;  121 877-885
• 5 Bornstein S R, Stratakis C A, Chrousos G P. Adrenocortical tumors: recent advances in basic concepts and clinical management.  Ann Intern Med. 1999;  130 759-771
• 6 Brown R D, Wisgerhof M, Carpenter P C, Brown G, Jiang N S, Kao P, Hegstad R. Adrenal sensitivity to angiotensin II and undiscovered aldosterone stimulating factors in hypertension.  J Steroid Biochem. 1979;  11 1043-1050
• 7 Chowdhury T A, Lasker S S. Coexisting renal artery stenosis and primary aldosteronism.  Nephrol Dial Transplant. 1997;  12 2735-2736
• 8 Conn J W. Presidental address. I. Paintig background. II. Primary aldosteronism, a new clinical syndrome.  J Lab Clin Med. 1955;  45 3-17
• 9 Conn J W, Knopf R F. Clinical characteristics of primary aldosteronism from analysis of 145 cases.  Am J Surg. 1964;  107 159-172
• 10 Deinum J, Derkx F H, Schalekamp M A. Improved immunoradiometric assay for plasma renin.  Clin Chem. 1999;  45 847-854
• 11 Diederich S, Quinkler M, Hanke B, Bahr V, Oelkers W. 11β-hydroxysteroid dehydrogenases: key enzymes in the action of mineralocorticoids and glucocorticoids.  Dtsch Med Wochenschr. 1999;  124 51-55
• 12 Dluhy R G, Lifton R P. Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis.  Steroids. 1995;  60 48-51
• 13 Fallo F, Barzon L, Biasi F, Altavilla G, Boscaro M, Sonino N. Zona fasciculata-like histotype and aldosterone response to upright posture are not related in aldosterone-producing adenomas.  Exp Clin Endocrinol Diabetes. 1998;  106 74-78
• 14 Fallo F, Sonino N, Boscaro M, Armanini D, Mantero F, Dorr H G, Knorr D, Kuhnle U. Dexamethasone-suppressible hyperaldosteronism: pathophysiology, clinical aspects, and new insights into the pathogenesis.  Klein Wochenschr. 1987;  65 437-444
• 15 Fardella C E, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.  J Clin Endocrinol Metab. 2000;  85 1863-1867
• 16 Fardella C E, Pinto M, Mosso L, Gomez-Sanchez C, Jalil J, Montero J. Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene.  J Clin Endocrinol Metab. 2001;  86 4805-4807
• 17 Farge D, Chatellier G, Pagny J Y, Jeunemaitre X, Plouin P F, Corvol P. Isolated clinical syndrome of primary aldosteronism in four patients with adrenocortical carcinoma.  Am J Med. 1987;  83 635-640
• 18 Feltynowski T, Ignatowska-Switalska H, Wocial B, Lewandowski J, Chodakowska J, Januszewicz W. Postural stimulation test in patients with aldosterone producing adenomas.  Clin Endocrinol (Oxf). 1994;  41 309-314
• 19 Fiad T M, Cunningham S K, Hayes F J, McKenna T J. Effects of nifedipine treatment on the renin-angiotensin-aldosterone axis.  J Clin Endocrinol Metab. 1997;  82 457-460
• 20 Fontes R G, Kater C E, Biglieri E G, Irony I. Reassessment of the predictive value of the postural stimulation test in primary aldosteronism.  Am J Hypertens. 1991;  4 786-791
• 21 Fraser R, Beretta-Piccoli C, Brown J J, Cumming A M, Lever A F, Mason P A, Morton J J, Robertson J I. Response of aldosterone and 18-hydroxycorticosterone to angiotensin II in normal subjects and patients with essential hypertension, Conn's syndrome, and nontumorous hyperaldosteronism.  Hypertension. 1981;  3 I87-92
• 22 Gallay B J, Ahmad S, Xu L, Toivola B, Davidson R C. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio.  Am J Kidney Dis. 2001;  37 699-705
• 23 Ganguly A. Current concepts - Primary aldosteronism.  N Engl J Med. 1998;  339 1828-1834
• 24 Ganguly A. Prevalence of primary aldosteronism in unselected hypertensive populations: screening and definitive diagnosis.  J Clin Endocrinol Metab. 2001;  86 4002-4004
• 25 Ganguly A, Dowdy A J, Luetscher J A, Melada G A. Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adrenal adenoma.  J Clin Endocrinol Metab. 1973a;  36 401-404
• 26 Ganguly A, Grim C E, Weinberger M H. Anomalous postural aldosterone response in glucocorticoid-suppressible hyperaldosteronism.  N Engl J Med. 1981;  305 991-993
• 27 Ganguly A, Melada G A, Luetscher J A, Dowdy A J. Control of plasma aldosterone in primary aldosteronism: distinction between adenoma and hyperplasia.  J Clin Endocrinol Metab. 1973b;  37 765-775
• 28 Geller D S, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai F TF, Sigler P B, Lifton R P. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy.  Science. 2000;  289 119-123
• 29 Gordon R D. Mineralocorticoid hypertension.  Lancet. 1994;  344 240-243
• 30 Gordon R D. Primary aldosteronism.  J Endocrinol Invest. 1995;  18 495-511
• 31 Gordon R D, Stowasser M, Tunny T J, Klemm S A, Finn W L, Krek A L. Clinical and pathological diversity of primary aldosteronism, including a new familial variety.  Clin Exp Pharmacol Physiol. 1991;  18 283-286
• 32 Gordon R D, Stowasser M, Tunny T J, Klemm S A, Rutherford J C. High incidence of primary aldosteronism in 199 patients referred with hypertension.  Clin Exp Pharmacol Physiol. 1994;  21 315-318
• 33 Gordon R D, Ziesak M D, Tunny T J, Stowasser M, Klemm S A. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers.  Clin Exp Pharmacol Physiol. 1993;  20 296-298
• 34 Guerin C K, Wahner H W, Gorman C A, Carpenter P C, Sheedy P F. 2. Computed tomographic scanning versus radioisotope imaging in adrenocortical diagnosis.  Am J Med. 1983;  75 653-657
• 35 Hambling C, Jung R T, Gunn A, Browning M C, Bartlett W A. Re-evaluation of the captopril test for the diagnosis of primary hyperaldosteronism.  Clin Endocrinol (Oxf). 1992;  36 499-503
• 36 Hensen J, Oelkers W. Mineralocorticoid-induced hypertension.  Med Klein. 1997;  92 273-278
• 37 Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients.  Arch Intern Med. 1981;  141 1589-1593
• 38 Irony I, Kater C E, Biglieri E G, Shackleton C H. Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma.  Am J Hypertens. 1990;  3 576-582
• 39 Kaplan N M. Caution about the overdiagnosis of primary aldosteronism.  Mayo Clin Proc. 2001;  76 875-876
• 40 Lafferty A R, Torpy D J, Stowasser M, Taymans S E, Lin J P, Huggard P, Gordon R D, Stratakis C A. A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22).  J Med Genet. 2000;  37 831-835
• 41 Lifton R P, Dluhy R G, Powers M, Rich G M, Cook S, Ulick S, Lalouel J M. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension.  Nature. 1992;  355 262-265
• 42 Lim P O, Dow E, Brennan G, Jung R T, MacDonald T M. High prevalence of primary aldosteronism in the Tayside hypertension clinic population.  J Hum Hypertens. 2000;  14 311-315
• 43 Lim P O, Jung R T, MacDonald T M. Is aldosterone the missing link in refractory hypertension? Aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity.  J Hum Hypertens. 2002;  16 153-158
• 44 Lim P O, Young W F, MacDonald T M. A review of the medical treatment of primary aldosteronism.  J Hypertens. 2001;  19 353-361
• 45 Lins P E, Adamson U. Plasma aldosterone-plasma renin activity ratio. A simple test to identify patients with primary aldosteronism.  Acta Endocrinol (Copenh). 1986;  113 564-569
• 46 Litchfield W R, Dluhy R G. Primary aldosteronism.  Endocrinol Metab Clin North Am. 1995;  24 593-612
• 47 Litchfield W R, New M I, Coolidge C, Lifton R P, Dluhy R G. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism.  J Clin Endocrinol Metab. 1997;  82 3570-3573
• 48 Loh K C, Koay E S, Khaw M C, Emmanuel S C, Young W F. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore.  J Clin Endocrinol Metab. 2000;  85 2854-2859
• 49 Lyons D F, Kem D C, Brown R D, Hanson C S, Carollo M L. Single dose captopril as a diagnostic test for primary aldosteronism.  J Clin Endocrinol Metab. 1983;  57 892-896
• 50 McKenna T J, Sequeira S J, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism.  J Clin Endocrinol Metab. 1991;  73 952-957
• 51 Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura G. Cardiovascular complications in patients with primary aldosteronism.  Am J Kidney Dis. 1999;  33 261-266
• 52 Oelkers W, Diederich S, Bahr V. Primary hyperaldosteronism without suppressed renin due to secondary hypertensive kidney damage.  J Clin Endocrinol Metab. 2000;  85 3266-3270
• 53 Pascoe L, Curnow K M, Slutsker L, Connell J M, Speiser P W, New M I, White P C. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2.  Proc Natl Acad Sci USA. 1992;  89 8327-8331
• 54 Quinkler M, Oelkers W, Diederich S. Clinical implications of glucocorticoid metabolism by 11β-hydroxysteroid dehydrogenases in target tissues.  Eur J Endocrinol. 2001;  144 87-97
• 55 Rayner B L, Opie L H, Davidson J S. The aldosterone/renin ratio as a screening test for primary aldosteronism.  S Afr Med J. 2000;  90 394-400
• 56 Rich G M, Ulick S, Cook S, Wang J Z, Lifton R P, Dluhy R G. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype.  Ann Intern Med. 1992;  116 813-820
• 57 Shigematsu Y, Hamada M, Okayama H, Hara Y, Hayashi Y, Kodama K, Kohara K, Hiwada K. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism.  Hypertension. 1997;  29 723-727
• 58 Stewart P M. Mineralocorticoid hypertension.  Lancet. 1999;  353 1341-1347
• 59 Stewart P M, Krozowski Z. 11β-hydroxysteroid dehydrogenase.  Vitam Horm. 1999;  57 249-324
• 60 Stewart P M, Krozowski Z S, Gupta A, Milford D V, Howie A J, Sheppard M C, Whorwood C B. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene.  Lancet. 1996;  347 88-91
• 61 Stokes G S, Monaghan J C, Roche J, Grunstein H, Gordon R D. Concurrence of primary aldosteronism and renal artery stenosis.  Clin Exp Pharmacol Physiol. 1992;  19 300-303
• 62 Stowasser M. Primary aldosteronism: revival of a syndrome.  J Hypertens. 2001;  19 363-366
• 63 Stowasser M, Bachmann A W, Huggard P R, Rossetti T R, Gordon R D. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension.  J Clin Endocrinol Metab. 2000;  85 3313-3318
• 64 Stowasser M, Gordon R D. Familial hyperaldosteronism.  J Steroid Biochem Mol Biol. 2001;  78 215-229
• 65 Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan.  J Endocrinol Invest. 1995;  18 370-373
• 66 Thibonnier M, Sassano P, Dufloux M A, Plouin P F, Corvol P, Menard J. A simple diagnostic test for primary hyperaldosteronism.  Presse Med. 1983;  12 1461-1466
• 67 Torpy D J, Gordon R D, Lin J P, Huggard P R, Taymans S E, Stowasser M, Chrousos G P, Stratakis C A. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene.  J Clin Endocrinol Metab. 1998;  83 3214-3218
• 68 Torpy D J, Stratakis C A, Chrousos G P. Hyper- and hypoaldosteronism.  Vitam Horm. 1999;  57 77-216
• 69 Trenkel S, Seifarth C, Schobel H, Hahn E G, Hensen J. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism.  Exp Clin Endocrinol Diabetes. 2002;  110 80-85
• 70 Udelsman R, Fishman E K. Radiology of the adrenal.  Endocrinol Metab Clin North Am. 2000;  29 27-42
• 71 Vallotton M B. Primary aldosteronism. Part I. Diagnosis of primary hyperaldosteronism.  Clin Endocrinol (Oxf). 1996b;  45 47-52
• 72 Vallotton M B. Primary aldosteronism. Part II. Differential diagnosis of primary hyperaldosteronism and pseudoaldosteronism.  Clin Endocrinol (Oxf). 1996a;  45 53-60
• 73 Weinberger M H, Fineberg N S. The diagnosis of primary aldosteronism and separation of two major subtypes.  Arch Intern Med. 1993;  153 25-29
• 74 Weinberger M H, Grim C E, Hollifield J W, Kem D C, Ganguly A, Kramer N J, Yune H Y, Wellman H, Donohue J P. Primary aldosteronism: diagnosis, localization, and treatment.  Ann Intern Med. 1979;  90 386-395
• 75 Young W F. Pheochromocytoma and primary aldosteronism: diagnostic approaches.  Endocrinol Metab Clin North Am. 1997;  26 801-827
• 76 Young W F, Stanson A W, Grant C S, Thompson G B, van Heerden J A. Primary aldosteronism: adrenal venous sampling.  Surgery. 1996;  120 913-920